Highlights: -NICE UK concludes that EVAR is cost-effective -Endovascular aortic questions to be settled by individual patient data meta-analysis -Kabnick: Limitations of the RECOVERY trial -Pedrini: TASC II guidelines are little help -Profile: John Mannick
